Aclarion

At Aclarion, we are committed to leading with strong clinical evidence as we work to advance the care of chronic low back pain. To support this mission, we are excited to announce the launch of our multi-center CLUE Trial to quantify how often Nociscan’s AI generated biomarker data changes surgical treatment plans. “Evidence points to a significant improvement in outcomes when Nociscan information is added to the treatment planning process. CLUE is specifically designed to quickly determine how influential Nociscan is in evaluating which discs a physician decides to treat,” stated Ryan D. Bond, Aclarion's Chief Strategy Officer Read the full annoucement here. https://lnkd.in/gF5NiQDD #ACON #ACONW #nasdaq #lowbackpain #CLUETrial #spinesurgery

Nociscan access is growing! We are thrilled to announce our first commercial agreement in Michigan with the Sheridan Community Hospital, making Nociscan available to patients throughout the greater Michigan area through industry leading neurosurgeon John Keller “As I work through how to best treat my patients, I’m excited to work with Sheridan Hospital and Nociscan to continue to develop safe, noninvasive, and cost-effective tools to help in the precise identification of disc pain,” said John Keller, MD  “Building upon the evidence that is already mounting in favor of using MR spectroscopy and Nociscan is important work that I’m enthusiastic to undertake.”     Learn more here. https://lnkd.in/erp9WZKd   #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

Nociscan is now approved for coverage by three major healthcare payer systems in the UK! We are excited to announce today that Vitality will now also cover the Nociscan solution for their members, expanding coverage of Nociscan to three of the four major private medical insurance groups in the UK, expanding access at The London Clinic to the more than 9 million London residents. Learn more here. https://lnkd.in/geTh9RcY “The London Clinic team saw the value in Nociscan after only 20 patients and have thus far delivered payer coverage from 3 of the top 4 private health insurance payers in the market. We expect to replicate The London Clinic success in driving payer coverage in other important markets in the U.S. and elsewhere around the world.” Brent Ness, CEO of Aclarion   #ACON #ACONW #nasdaq #nociscan #spinecare #lowbackpain

Marc Viscogliosi, a spine industry thought leader and The State of Spine Surgery Think Tank, a leading forum for provocative discussion and debate - the pair are a perfect combination for advancing ideas and the industry. #lowbackpain #augmentedintelligence #precisionmedicine #personalizedhealth #virtualdiscogram #disruptiveinnovation #spine #spinehealth #chemicalboomarkers #spectroscopy #degenerativediscdisease

Thank you Marc Viscogliosi for an impactful presentation on addressing the gaps in spine care at the recent State of Spine Surgery Think Tank. Aclarion was honored to be mentioned as an important innovator in driving improved patient care. #ACON #ACONW #nasdaq #spinesurgery #lowbackpain Spine BioPharma

Did you know that a simple scan in a traditional MRI can provide significant personalized biomarker data about the health of the discs in the lower back? The Nociscan solution is the world’s only SaaS platform to transform this biomarker data into a simple, streamlined, easy-to-use report that helps physicians optimize the unique treatment strategy for each chronic low back pain patient. Learn more today at www.aclarion.com. #ACON #ACONW #nasdaq #nociscan #lowbackpain

Evidence demonstrates that when discs identified by Nociscan are treated as part of the surgical strategy, patients experience a significantly greater success rate following surgery for chronic low back pain. To learn more about the evidence supporting the use of Nociscan to inform treatment decisions for low back pain, visit https://lnkd.in/gWQiz8kv. #ACON #ACONW #nasdaq #chroniclowbackpain #spinesurgery #clinicalevidence #clinicaldata

Aclarion was pleased to support the #aspn2024 annual meeting which featured a panel discussion, “Advanced Modalities for Diagnosis of Painful Lumbar Discs: MR Spectroscopy, Artificial Intelligence, and Chemical Biomarkers” by physician leaders Michael Doris, MD and Melissa Murray, MD. Thank you for the invigorating discussion about the future of diagnosing chronic low back pain and the importance of solutions like #Nociscan in the driving the innovation needed to advance patient care.   #ACON #ACONW #nasdaq #spinesurgery #lowbackpain

Are you ready to learn more about how the Nociscan solution can help improve treatment outcomes for patients suffering from chronic low back pain? Join us this week at ASPN Booth 187 to discover the latest clinical data regarding the Nociscan solution and learn how you can bring it to your spine patients. Hope to see you in Miami! #ACON #ACONW #nasdaq #ASPN #ASPN2024 #ASPN24 #spine #spinesurgery #lowbackpain

Aclarion achieves additional key commercial milestone by securing second payer coverage decision by Aviva Broker UK; a major private payor in the UK. This coverage decision, along with the previous coverage by AXA, expands Nociscan access to approximately 45% of patients with private payer insurance in the greater London area. Read more here: https://lnkd.in/g2_SM4fs. #spinesurgery #spine #lowbackpain #nasdaq #ACON #ACONW